Wednesday, February 21, 2018 10:15 PM ET
RA Pharmaceuticals (RARX) sees Significant Insider buy Extending Trend of purchases over Last Quarter
There was a significant insider buy in RA Pharmaceuticals shares today as revealed in a filing with the SEC. One insider — NEW ENTERPRISE ASSOCIATES 13 LP, 10% Owner — acquired 2,000,000 shares in the company having a net market value of approximately $12,000,000. There have been 2 insiders with buy/sell transactions in the past 90 days prior to this filing. All of these trades have been buys resulting in the acquisition of 5,000,000 company shares. Adding the most recent activity to this 90-day history indicates insider trades have seen net purchases of 7,000,000 shares and have averaged 2,333,333 shares per transaction over this time period.
Over the last 90 days, the number of insider buy/sell trades at RA Pharmaceuticals is greater than the 281-company peer group average. Bio Therapeutic Drugs peer group saw 317 buy/sell trades during this period for an average of 1.1 transactions per company. The number of shares per buy/sell trade for RA Pharmaceuticals insiders was also higher. Within the peer group there were 25,857,165 shares purchased and 16,029,831 shares sold with company insiders having bought 50,397 shares on average.
For the purpose of evaluating significant insider buying and selling all trades reported to the SEC that involve awards, options, exercise of derivative securities, company buy-backs, taxes, gifts, shares acquired via inheritance and tenders or exchange offers have been eliminated in data sourced to compose and write this story.
Using proprietary Natural Language Generation (NLG) technology, UpTick evaluates corporate insider filings reported to the SEC and creates real-time news and analysis to report the most significant insider transactions based on transaction type, size and historical trends.
For more information, contact UpTick at firstname.lastname@example.org. Copyright 2018 UpTick Data Technologies. All rights reserved.